Evidence map›Paper›PMID 41390462›Full record

ArticleNature communications2025

Semi-inductive dataset construction and framework optimization for practical drug target interaction prediction with ScopeDTI.

Yigang Chen, Xiang Ji, Ziyue Zhang, Zihao Zhu, Yuming Zhou, Chang Su, Yang-Chi-Dung Lin, Hsi-Yuan Huang, Kangping Wei, Yi Lai and 10 more

Abstract read
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Pharmaceuticals (Basel, Switzerland) · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Yigang Chen *School of Medicine, The Chinese University of Hong Kong, Shenzhen, Longgang District, Shenzhen, Guangdong, China.ORCID http://orcid.org/0009-0008-7290-0047
Xiang Ji *School of Medicine, The Chinese University of Hong Kong, Shenzhen, Longgang District, Shenzhen, Guangdong, China.ORCID http://orcid.org/0009-0005-0820-4862
Ziyue Zhang *School of Medicine, The Chinese University of Hong Kong, Shenzhen, Longgang District, Shenzhen, Guangdong, China.
Zihao Zhu *School of Medicine, The Chinese University of Hong Kong, Shenzhen, Longgang District, Shenzhen, Guangdong, China.
Yuming ZhouSchool of Medicine, The Chinese University of Hong Kong, Shenzhen, Longgang District, Shenzhen, Guangdong, China.
Chang SuSchool of Medicine, The Chinese University of Hong Kong, Shenzhen, Longgang District, Shenzhen, Guangdong, China.
Yang-Chi-Dung LinSchool of Medicine, The Chinese University of Hong Kong, Shenzhen, Longgang District, Shenzhen, Guangdong, China.
Hsi-Yuan HuangSchool of Medicine, The Chinese University of Hong Kong, Shenzhen, Longgang District, Shenzhen, Guangdong, China.
Kangping WeiSchool of Medicine, The Chinese University of Hong Kong, Shenzhen, Longgang District, Shenzhen, Guangdong, China.
Yi LaiSchool of Medicine, The Chinese University of Hong Kong, Shenzhen, Longgang District, Shenzhen, Guangdong, China.
Ke ChenSchool of Medicine, The Chinese University of Hong Kong, Shenzhen, Longgang District, Shenzhen, Guangdong, China.
Xingqiao LinSchool of Medicine, The Chinese University of Hong Kong, Shenzhen, Longgang District, Shenzhen, Guangdong, China.
Yangyi ZhangSchool of Medicine, The Chinese University of Hong Kong, Shenzhen, Longgang District, Shenzhen, Guangdong, China.
Jiehui FuSchool of Medicine, The Chinese University of Hong Kong, Shenzhen, Longgang District, Shenzhen, Guangdong, China.
Yixian HuangSchool of Medicine, The Chinese University of Hong Kong, Shenzhen, Longgang District, Shenzhen, Guangdong, China.ORCID http://orcid.org/0009-0004-2601-2875
Shidong CuiSchool of Medicine, The Chinese University of Hong Kong, Shenzhen, Longgang District, Shenzhen, Guangdong, China.
Shih-Chung YenSchool of Medicine, The Chinese University of Hong Kong, Shenzhen, Longgang District, Shenzhen, Guangdong, China.
Tao ZhangBetter Way Group-Chinese University of Hong Kong (Shenzhen) Warshel Joint Laboratory for skin health and active molecule innovation, Longgang District, Shenzhen, Guangdong, China.ORCID http://orcid.org/0009-0007-5655-3287
Arieh WarshelDepartment of Chemistry, University of Southern California, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0001-7971-5401
Hsien-Da HuangSchool of Medicine, The Chinese University of Hong Kong, Shenzhen, Longgang District, Shenzhen, Guangdong, China. huanghsienda@cuhk.edu.cn.ORCID http://orcid.org/0000-0003-2857-7023

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Deep learning-based drug-target interaction (DTI) prediction methods have demonstrated strong performance; however, real-world applicability remains constrained by limited data diversity and modeling complexity. To address these challenges, we propose SCOPE-DTI, a unified framework combining a large-scale, balanced semi-inductive human DTI dataset with advanced deep learning modeling. SCOPE-DTI is constructed from 13 public repositories and expands data volume by up to 100-fold compared to common benchmarks such as the Human dataset. The SCOPE model integrates three-dimensional protein and compound representations, graph neural networks, and bilinear attention mechanisms to effectively capture cross domain interaction patterns and outperform state-of-the-art methods across various DTI prediction tasks. Additionally, SCOPE-DTI provides a user-friendly interface and database. We further demonstrate its effectiveness by experimentally identifying anticancer targets of two bioactive natural compounds. By offering comprehensive data, advanced modeling, and accessible tools, SCOPE-DTI accelerates drug discovery research.

Indexed as

Deep LearningDrug DiscoveryDatabases, FactualHumansNeural Networks, Computer

Identifiers

PMID41390462
PMCPMC12748854

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.